^
Association details:
| Biomarker: | FGFR3 S249C |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Excerpt:
Ponatinib inhibited growth of UMUC14 (FGFR3S249C) and MGH-U3 (FGFR3Y375C) cells with GI50 values of 103 and 181 nmol/L, respectively, but had no effect on growth of T24 cells that express wild-type FGFR3 (GI50 > 1,000 nmol/L; Fig. 3A; ref. 41).
DOI:
10.1158/1535-7163.MCT-11-0450
